

N. ADINARAYANA & ASSOCIATES
CHARTERED ACCOUNTANTS

No.404, VICTORY AVENUE
16, 4th FLOOR
HOSPITAL ROAD
BANGALORE-560 053.
Mobile No: 9844316588/41695247

E-mail ID: n_adinarayana@hotmail.com

INDEPENDENT AUDITOR'S REPORT

To,
The Members of Quadragen Vethealth Private Limited

Report on the Audit of Financial Statements

Opinion

We have audited the financial statements of M/s. Quadragen Vethealth Private Limited ("the Company") which comprises the Balance Sheet as at March 31, 2026, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the standalone Statement of Cash Flows for the year then ended, and notes to the financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2026, its Profit (including Other comprehensive income), changes in equity and its cash flows for the year ended on that date

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Company's Board of Directors is responsible for the other information. The other information comprises the Board's Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.



We have nothing to report in this regard.

Responsibility of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls systems in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), as amended, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c. The Balance Sheet, the Statement of Profit and Loss including other comprehensive income, the Statement of Changes in Equity and the Standalone Statement of Cash Flows dealt with by this Report are in agreement with the books of account.
 - d. In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e. On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors are disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
 - g. In our opinion, the managerial remuneration for the year ended March 31, 2026 has been paid / provided by the Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Act.



h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. The Company has no litigations pending and hence no disclosures of the same are made in the financial statements.
- ii. The Company does not have any long-term contracts including derivative contracts and there were no material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv.
 - a. On the basis of the written representations received from the Board, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - b. On the basis of the written representations received from the Board, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - c. Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v. During the year there were no amounts declared or paid as dividend by the company.
- vi. Based on our examination which included test checks, the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated with effect from 24th April 2024. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

PLACE: BANGALORE

DATE: 08.05.2026

For N.ADINARAYANA & ASSOCIATES

Chartered Accountants

N. Adinarayana
N. ADINARAYANA

PROPRIETOR



Membership No: 202948

Firm's registration No: 0070865

UDIN - 26202948EHJXTU5554

Annexure A to the Independent Auditors' Report

Referred to in paragraph 1 under the heading 'Report on Other Legal & Regulatory Requirement' of our report of even date to the financial statements of the Company for the year ended March 31, 2026:

1)

- a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The company does not hold any intangible assets and hence no comment is made on the maintenance or otherwise of the particulars of intangible assets.

- b) According to the information and explanation provided to us, Property, Plant and Equipment have been physically verified by the management at reasonable intervals, which in our opinion, is reasonable having regard to the size of the company and nature of its assets. No material discrepancies between the books record and the physical fixed assets have been noticed.
- c) The Company does not own any immovable property (other than immovable properties where the Company is the lessee and lease agreements are duly executed in favour of the Company).
- d) The Company has not revalued any of its Property, Plant and Equipment (including right-of-use assets) and intangible assets during the year.
- e) Based on the information and explanations furnished to us, no proceedings have been initiated on or are pending against the Company for holding benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended in 2016) (formerly the Benami Transactions (Prohibition) Act, 1988 (45 of 1988)) and Rules made thereunder, and therefore the question of our commenting on whether the Company has appropriately disclosed the details in its financial statements does not arise.

2)

- a) The inventory has been physically verified during the year by the management at reasonable intervals. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory.
- b) During the year, the company has been sanctioned working capital limits in excess of Rs. 5 crore, in aggregate, from banks on the basis of security of current assets. The Company has filed quarterly returns/ statements with such banks, which are in agreement with the books of account of the company.

- 3) According to the information and explanation given to us, the Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability partnerships or other parties covered in the Register maintained under Section 189 of the Act. Therefore, the provisions of clause 3 (iii) (a) to (f) of the order is not applicable to the Company.

- 4) The Company has not made any loans and investments, guarantees, and security covered by provisions of Section 185 and 186 of the Act. Consequently, comment on clause 3(iv) of the order is not applicable



- 5) The Company has not accepted any deposits from the public or none of amounts which are deemed to be deposits. Hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.
- 6) According to the information and explanations given to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company. Accordingly, paragraph 3(vi) is not applicable to the company.
- 7)
- a) In our opinion and according to the information and explanations given to us, and on the basis of our examination of the records, the Company has been generally regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities. There were no material statutory dues in arrears as at 31st March 2026 for a period of over six months from the date they became payable.
- b) According to the information and explanation given to us, there are no dues of Goods and Services Tax, provident fund, employees' state insurance, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues outstanding on account of any dispute
- 8) According to the information and explanation given to us, there were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- 9)
- a) In our opinion and according to the information and explanations given by the management, the Company has not defaulted repayment of loans or borrowings to banks or financial institutions. The Company has neither taken any loan from government nor has issued any debentures.
- b) According to the information and explanations given to us and on the basis of our audit procedures, we report that the company has not been declared willful defaulter by any bank or financial institution or government or any government authority.
- c) In our opinion and according to the information and explanations given to us, the company has utilized the money obtained by way of term loans during the year for the purposes for which they were obtained.
- d) In our opinion and based on the explanation given to us, and on our overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been utilised during the year for long-term purposes.
- e) In our opinion and based on the explanation given to us along with our overall examination of the financial statements of the Company, the Company it has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates of joint ventures.



- f) According to the information and explanations to us, the Company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.

10)

- a) The Company has not raised monies by way of initial public offer or further public offer (including debt instruments) during the year. Accordingly, the reporting under clause 3(x)(a) of the Order are not applicable to the Company.
- b) The Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) during the year. Accordingly reporting under clause 3(x)(b) of the Order are not applicable to the Company.

11)

- a) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company and no fraud on the Company has been noticed or reported during the period covered by audit.
- b) No report under sub-section (12) of section 143 of the Act has been filed with the Central Government, for the period covered by our audit.
- c) According to the information and explanations given to us including the representation made to us by the management of the Company, there are no whistle blower complaints received by the company during the year;

12) The Company is not a Nidhi Company. Accordingly, reporting under clause 3(xii) of the Order is not applicable to the Company.

13) In our opinion, all transactions with the related parties are in compliances with Section 177 & 188 of Companies Act, 2013 and are disclosed in the Financial Statements as required by the applicable accounting standards.

14) In our opinion and based on our examination, the company is not required to have an internal audit system as per provisions of Section 138 of the Act.

15) Based on the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company and hence not commented upon.

16) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934 and hence reporting under clause 3(xvi)(a), (b) and (c) of the Order is not applicable. As per the information and representation provided by the management, there are Two CIC within the group (as defined in Core Investment Companies (Reserve Bank) Directions, 2016).

17) The company has not incurred cash losses in the financial year and in the immediately preceding financial year.

18) There has been no resignation of the statutory auditors of the Company during the year.
Accordingly, reporting under clause 3(xviii) of the Order is not applicable to the Company.



- 19) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- 20)(i) In respect of other than ongoing projects, there are no unspent amounts that are required to be transferred to a fund specified in Schedule VII of the Companies Act (the Act), in compliance with second proviso to sub section 5 of section 135 of the Act.
(ii) There are no unspent amounts in respect of ongoing projects, that are required to be transferred to a special account in compliance of provision of sub section (6) of section 135 of Companies Act.
- 21) The reporting under Clause 3(xxi) of the Order is not applicable in respect of audit of stand-alone financial statements of the Company. Accordingly, no comment has been included in respect of said clause under this report.

PLACE: BANGALORE

DATE: 08.05.2026

For N.ADINARAYANA & ASSOCIATES

Chartered Accountants

N. Adinarayana

N. ADINARAYANA

PROPRIETOR

Membership No: 202948

Firm's registration No: 007086S

UDIN - 26202948EHJXTU5554



Annexure B to the Independent Auditors' Report

Referred to in paragraph 2(f) under the heading 'Report on Other Legal & Regulatory Requirement' of our report of even date to the financial statements of the Company for the year ended March 31, 2026:

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We were engaged to audit the internal financial controls over financial reporting of **Quadragen Vethealth Private Limited** ("the Company") as of March 31, 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, to the extent applicable to an audit of internal financial controls, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in



accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

- 1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- 2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- 3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls systems over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31st 2026, based on internal control over financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

For N.ADINARAYANA & ASSOCIATES

Chartered Accountants

N. Adinarayana

N. ADINARAYANA

PROPRIETOR



PLACE: BANGALORE

DATE: 08.05.2026

Membership No: 202948

Firm's registration No: 0070865

UDIN - 26202948EHJXTU5554

QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Balance Sheet

(Amount in Rs. Lakhs unless otherwise stated)

	Note	As at 31 March 2026	As at 31 March 2025
ASSETS			
Non-Current Assets			
Property, Plant and Equipments	2	2,145.11	2,064.45
Capital work-in-progress		1.87	-
Financial Assets			
- Other Financial Assets	3	32.73	32.73
Other Non Current Assets	4	340.53	332.82
Income Tax Asset (Net)	20	93.14	-
Deferred Tax Asset (Net)	14		
Total non-current assets		2,613.38	2,430.00
Current Assets			
Inventories	5	2,433.01	1,952.56
Financial Assets			
- Current Investment	6	11,116.32	8,069.93
- Trade receivables	7	3,075.81	1,663.02
- Cash and cash equivalents	8	205.56	591.90
- Other Current Financial Assets	9	0.17	0.12
Current Tax Assets	10	115.37	111.78
Other Current Assets	11	181.53	175.14
Total current assets		17,127.77	12,564.45
Total Assets		19,741.15	14,994.45
EQUITY AND LIABILITIES			
Equity			
Equity Share Capital	12	600.00	600.00
Other Equity		16,146.30	12,976.19
Total equity		16,746.30	13,576.19
Non-Current Liabilities			
Provisions	13	131.60	88.45
Lease Liability	2A	0.00	-
Deferred Tax Liabilities (net)	14	448.66	389.79
Total non-current liabilities		580.26	478.24
Current Liabilities			
Lease Liabilities	2A	2.34	-
Financial liabilities			
- Borrowings	15	649.53	191.29
- Trade Payables			
(a) Total outstanding dues of micro and small enterprises	16	82.02	71.44
(b) Total outstanding dues of other than micro and small enterprises		1,281.13	616.25
Provisions	17	24.33	18.93
Other current liabilities	18	375.24	27.83
Current Tax Liabilities	19	-	14.28
Total Current Liabilities		2,414.59	940.02
Total liabilities		2,994.85	1,418.26
Total Equity and Liabilities		19,741.15	14,994.45

Material Accounting Policies

See accompanying notes to the financial statements

As per our report of even date annexed

For N Adinarayana & Associates

Chartered Accountants


N Adinarayana

Proprietor

Membership No :- 202948

Firm Registration No:- 0070865

UDIN: 26202948EHXTU5554

Place: Bangalore

Date: 8 May, 2026

For and on behalf of the Board of Directors


Lakshmikanth Yadav

Executive Director

DIN. 03171140


Rajeevalochan Dinamani

Executive Director

DIN. 03171174

Place: New Delhi

Date: 8 May, 2026

Place: New Delhi

Date: 8 May, 2026

QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Statement of Profit and Loss

(Amount in Rs. Lakhs unless otherwise stated)

	Note	For the period ended 31 March 2026	For the year ended 31 March 2025
REVENUE			
Revenue from Operations	21	12,014.29	12,679.57
Other Income	22	302.83	684.77
Total Income		12,317.12	13,364.34
EXPENSES			
Cost of Material Consumed	23	5,571.40	6,167.74
Purchase Of Stock In Trade		56.34	458.38
Changes in Inventory of Finished Goods and Work in Progress	24	93.29	(371.32)
Employee Benefits Expense	25	1,071.76	935.53
Finance Costs	26	20.11	20.17
Depreciation & Amortization Expenses	27	127.84	126.60
Other Expenses	28	1,423.41	1,355.92
Total Expenses		8,364.15	8,693.02
Profit before exceptional items and tax		3,952.97	4,671.32
Exceptional items		-	-
Profit before tax		3,952.97	4,671.32
Tax expense			
Current tax		717.55	791.90
Previous years		(0.84)	-
Deferred tax		58.87	61.60
MAT credit utilised		-	0.14
Total tax expenses		775.58	853.64
Profit after tax		3,177.39	3,817.68
Other Comprehensive Income			
Items that will not be reclassified to profit & loss			
(i) Re-measurement Gain/(Loss) on Defined Benefit Plans		(9.23)	(6.15)
(ii) Income tax relating to above		2.69	1.79
Other Comprehensive Income/(Expense) for the year (Net of Tax)		(6.54)	(4.36)
Total Comprehensive Income		3,170.85	3,813.32
EARNING PER SHARE			
Basic and diluted	29	52.96	54.51

Material Accounting Policies

1

See accompanying notes to the financial statements

As per our report of even date annexed

For N Adinarayana & Associates

Chartered Accountants

N Adinarayana

Proprietor

Membership No :- 202948

Firm Registration No:- 0070865

UDIN: 26202948EHXTU5554

Place: Bangalore

Date: 8 May, 2026

For and on behalf of the Board of Directors


Lakshmikanth Yadav

Executive Director

DIN. 03171140

Rajeevalochan Dinamani

Executive Director

DIN. 03171174

Place: New Delhi

Date: 8 May, 2026

Place: New Delhi

Date: 8 May, 2026

QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Statement of Cash Flow

(Amount in Rs. Lakhs unless otherwise stated)

Particulars	For the period ended 31 March 2026	For the year ended 31 March 2025
A. Cash Flow from Operating Activities		
Net Profit before exceptional items and tax	3,952.97	4,671.34
Adjustments for:-		
Depreciation and amortisation	127.84	126.59
Finance Cost	20.11	20.17
Profit/(loss) on mutual fund investment	(214.03)	-
Interest Income	(4.90)	(0.01)
Loss/(Profit) on sale of Assets	(1.42)	21.62
Provisions	9.04	-
Effect of unrealised gain/(loss)	5.92	-
Operating profit before working capital changes	3,895.53	4,839.71
Changes in working capital		
Trade Receivables	(1,381.37)	211.09
Other current and non-current assets	(113.77)	125.53
Inventories	(480.44)	(682.60)
Trade Payables	653.33	(24.24)
Other current and non-current liabilities	480.24	(823.97)
Cash Generated from Operations	3,053.52	3,645.52
Net income tax(paid)/refunds received	(826.73)	(777.62)
Net Cash flow from/(used in) operating activities (A)	2,226.79	2,867.90
B. Cash flow from Investing Activities		
Capital Expenditure	(198.68)	(318.63)
Proceeds from Sale of assets	2.77	30.53
Interest Income	1.25	0.01
Sale/(Purchase) of Investments (Net)	(2,832.36)	930.22
Net Cash flow from/(used in) Investing Activities (B)	(3,027.02)	642.13
C. Cash flow from Financing Activities		
Buyback of equity shares including buyback tax & other transaction costs	-	(3,082.44)
Proceeds/(Repayment) from short-term borrowings (Net)	429.81	(2.31)
Repayment of lease liabilities	(0.06)	-
Interest and Financial Charges	(20.01)	(20.17)
Net Cash Flow from/(used in) Financing Activities (C)	409.74	(3,104.92)
Net Increase/(decrease) in Cash and Cash Equivalents (A+B+C)	(390.49)	405.11
Cash and cash equivalents at the beginning of the year	591.90	186.79
Exchange differences on translation of foreign currency balances	4.15	-
Cash and cash equivalents at the end of the year	205.56	591.90

As per our report of even date annexed

For N Adinarayana & Associates

Chartered Accountants

N Adinarayana

Proprietor

Membership No :- 202948

Firm Registration No:- 0070865

UDIN: 26202948EHJXTU5554

Place: Bangalore

Date: 8 May, 2026

For and on behalf of the Board of Directors

Lakshmikanth Yadav

Executive Director

DIN. 03171140

Rajeevalochan Dinamani

Executive Director

DIN. 03171174

Place: New Delhi

Date: 8 May, 2026

Place: New Delhi

Date: 8 May, 2026

QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Statement of Changes in Equity

(Amount in Rs. Lakhs unless otherwise stated)

A. Equity Share Capital		
Particulars	Number of Shares	Amount
Balance as on 1 April 2024	8,000,000	800.00
Changes during the year	(2,000,000)	(200.00)
Balance as on 31 March 2025	6,000,000	600.00
Balance as on 1 April 2025	6,000,000	600.00
Changes during the year	-	-
Balance as on 31 March 2026	6,000,000	600.00

B. Other Equity

Particulars	Retained Earnings	Capital Reserve	Special Economic Zone Re-investment Reserve Account	Capital Redemption Reserve Account	Other comprehensive income	Total Other Equity
Balance as on 1 April 2024	10,182.16	88.99	1,842.09	-	(67.96)	12,045.28
Profit(Loss) for the period	3,817.71	-	-	-	(4.36)	3,813.35
Buyback of Shares	(2,882.44)	-	-	-	-	(2,882.44)
Transfer to Capital Redemption Reserve Account	(200.00)	-	-	200.00	-	-
Transfer to Special Economic Zone Re-investment Reserve Account	(1,489.53)	-	1,489.53	-	-	-
Balance as on 31 March 2025	9,427.90	88.99	3,331.62	200.00	(72.32)	12,976.19
Balance as on 1 April 2025	9,427.90	88.99	3,331.62	200.00	(72.32)	12,976.19
Profit(Loss) for the period	3,177.38	-	-	-	(6.54)	3,170.84
Adjustment for Ind AS 116	(0.72)	-	-	-	-	(0.72)
Transfer to Special Economic Zone Re-investment Reserve Account	(1,318.79)	-	1,318.79	-	-	-
Utilisation of Special Economic Zone Re-investment Reserve Account	325.82	-	(325.82)	-	-	-
Balance as on 31 March 2026	11,611.60	88.99	4,324.59	200.00	(78.86)	16,146.30

As per our report of even date annexed

For N Adinarayana & Associates

Chartered Accountants



N Adinarayana

Proprietor

Membership No. : 202948

Firm Registration No:- 0070865

UDIN: 26202948EHXTU5554

For and on behalf of the Board of Directors

[Signature]
Lakshminanth Yadav
 Executive Director
 DIN. 03171140

[Signature]
Rajeevalochan Dinamani
 Executive Director
 DIN. 03171174

Place: Bangalore

Date: 8 May, 2026

Place: New Delhi

Date: 8 May, 2026

Place: New Delhi

Date: 8 May, 2026

QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

The Company overview

Quadragen Vethealth Private Limited ('the Company') was incorporated on September 15, 2010 as a private limited company under the Companies Act, 1956. The registered office of the Company is located at 1/1 Akka Complex, 14th Cross, 5th Main, R.M.V. 2nd Stage, Dollars Colony, Chikkamaranahalli, Bangalore, Karnataka, India, 560094.

The company operates in the business of manufacturing and selling of Animal Nutrition Products including Feed Additives & Growth Promoters.

These financial statements were approved and adopted by the Board of Directors of the Company in their meeting held on 08 May, 2026.

Note 1- Basis of Preparation of Financials Statements and Material Accounting policies:

1.1 Basis of Preparation of Financials Statements

The Financial Statements have been prepared in accordance with Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) (Amendment) Rules, 2023 and relevant provisions of the Companies Act, 2013.

These financial statements have been prepared and presented under the historical cost convention, on the accrual basis of accounting except for certain financial assets and financial liabilities that are measured at fair values at the end of each reporting period, as stated in the accounting policies set out below. The accounting policies have been applied consistently over all the periods presented in these financial statements.

Functional and Presentational currency

Company's financial statements are presented in Indian Rupees (Rs.), which is also its functional currency.

Rounding of amounts

All amounts disclosed in the financial statements and notes have been rounded off to the nearest lakhs as per the requirement of Schedule III, unless otherwise stated.

1.2 Use of estimates

The preparation of financial statements in conformity with Ind AS requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

Appropriate changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

1.3 Classification of Assets and Liabilities as Current and Non-Current

All Assets and Liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013. Based on the nature of product & activities of the Company and their realisation in cash and cash equivalent, the Company has determined its operating cycle as twelve months for the purpose of current and non-current classification of assets and liabilities. Deferred tax assets and liabilities are classified as non-current assets and liabilities.

1.4 Material accounting policies

(a) Property, Plant and Equipment

On transition to IND AS, the company had adopted optional exception under IND AS 101 to measure Property, Plant and Equipment (PPE) at fair value. Consequently, the fair value had been assumed to be deemed cost of PPE on the date of transition. Subsequently PPE were carried at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditure that is directly attributable to the acquisition of the items.

PPE acquired are stated at cost net of tax/duty credit availed, less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenses directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

CWIP

Capital work-in-progress includes cost of PPE under installation / under development as at the balance sheet date. Advances paid towards the acquisition of PPE outstanding at each balance sheet date is classified as capital advances under other non-current assets.

Subsequent expenditures relating to PPE is capitalized only when it is probable that future economic benefits associated with these will flow to the Company and the costs to the item can be measured reliably. Repairs and maintenance costs are recognized in net profit in the statement of profit and loss when incurred. The cost and related accumulated depreciation are eliminated from the financial statements upon sale or retirement of the asset and the resultant gain or losses are recognized in the statement of profit and loss.

Depreciation will be charged from the date the asset is available for use, i.e., when it is in the location and condition necessary for it to be capable of operating in the manner intended by management. The residual values, useful lives and methods of depreciation of PPE are reviewed at each financial year end and adjusted prospectively, if appropriate.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

Depreciation on Buildings, Plant & Machinery and Other Assets is provided as per Straight method at the rate as prescribed under Schedule II of Companies Act, 2013. Useful life of the assets are as follows:

Lease Hold Land: Lease period

Building: 20-30 years

Vehicles: 8 years

Computers: 3 years

Plant & Machinery: 15 years

Furniture & Fixtures: 10 years

Electrical installations and equipment: 10-15 years

Office Equipments: 5 years

Lab Equipments: 10 years

(b) Intangible Assets:

Intangible Assets are recognised, if the future economic benefits attributable to the assets are expected to flow to the company and cost of the asset can be measured reliably. All other expenditure is expensed as incurred. The same are amortised over the expected duration of benefits. Such intangible assets are measured at cost less any accumulated amortisation and impairment losses, if any and are amortised over their respective individual estimated useful life on straight line method.

The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period and adjusted prospectively, if appropriate.

(c) Impairment

The carrying amount of PPEs & Intangible assets are reviewed at each Balance Sheet date to assess impairment if any, based on internal / external factors. An asset is treated as impaired, when the carrying cost of asset exceeds its recoverable value, being higher of value in use and net selling price. An impairment loss is recognised as an expense in the Statement of Profit and Loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is reversed, if there has been an improvement in recoverable amount.

(d) Revenue Recognition

Revenue from contracts with customers is recognized on transfer of control of promised goods or services to a customer at an amount that reflects the consideration to which the Company is expected to be entitled to in exchange for those goods or services.

Revenue from sale of goods is recognised at the point in time when control of the goods is transferred to the customer involving single performance obligation, which is generally at the time of delivery as per the contract. It is measured at the fair value of the consideration received or receivable, net of returns, trade discounts, volume rebates and goods and services tax.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

Contract balances:

Contract assets:

A contract asset is the right to consideration in exchange for goods transferred to the customer. If the Company performs by transferring goods to a customer before the customer pays consideration or before payment is due, a contract asset is recognised for the earned consideration that is conditional.

Trade receivables:

A receivable represents the Company's right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due).

Contract liabilities:

A contract liability is the obligation to transfer goods to a customer for which the Company has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before the Company transfers goods to the customer, a contract liability is recognised when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognised as revenue when the Company performs under the contract.

Revenue from services is recognized over period of time on performance of obligation as per the terms of the agreement. However, revenue from services comprising of conversion of raw material into finished products and such other services, involving single performance obligation, are recognised at a point in time.

Interest income from a financial asset is recognised using effective interest rate method.

Dividend income is recognised when the Company's right to receive the payment has been established.

(e) Inventories

Raw materials, components, stores and spares and packing material are valued at lower of cost and net realizable value. Goods-in-Transit are stated 'at cost'. However, materials and other items held for use in production of inventories are not written down below cost if the finished goods in which they will be incorporated are expected to be sold at or above cost. The comparison of cost and net realizable value is made on an item-by item basis.

- Cost of raw materials is determined based on Weighted average method.
- Cost of Finished goods and Work in progress includes cost of materials, direct labour and an appropriate proportion of freight, overheads, Insurance, direct costs and non-refundable tax/ duties (as applicable) to bring the inventory to the present location and condition.
- Cost of Scrap materials are valued at net realizable value.

(f) Cash and Cash Equivalents

Cash and cash equivalents comprise cash on hand, cash at bank and demand deposits with banks with an original maturity of three months or less which are subject to an insignificant risk of change in value.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

(g) Cash Flow Statements

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

(h) Foreign Currency Transactions

Initial Recognition

On initial recognition, for monetary items transactions in foreign currencies entered into by the Company are recorded in the functional currency (i.e. Indian Rupees), by applying to the foreign currency amount, the spot exchange rate between the functional currency and the foreign currency at the date of the transaction. Exchange differences arising on foreign exchange transactions settled during the year are recognized in the Statement of Profit and Loss.

For non-monetary items that are measured in terms of historical cost in a foreign currency are recorded using the exchange rates at the date of the transaction. In case of an asset, expense or income where a non-monetary advance is paid/received, the date of transaction is the date on which the advance was initially recognised. If there were multiple payments or receipts in advance, multiple dates of transactions are determined for each payment or receipt of advance consideration.

Measurement of foreign currency items at reporting date:

Foreign currency monetary items of the Company are translated at the closing exchange rates. Non-monetary items that are measured at historical cost in a foreign currency, are translated using the exchange rate at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency, are translated using the exchange rates at the date when the fair value is measured.

The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in OCI or Statement of Profit and Loss are also recognised in OCI or Statement of Profit and Loss, respectively).

(i) Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

(i) Financial Assets

Initial recognition and measurement:

The Company recognizes a financial asset in its Balance Sheet when it becomes party to the contractual provisions of the instrument. All financial assets are recognized initially at fair value, plus in the case of financial assets not recorded at fair value through profit or loss ("FVTPL"), transaction costs that are attributable to the acquisition of the financial asset.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

Where the fair value of a financial asset at initial recognition is different from its transaction price, the difference between the fair value and the transaction price is recognized as a gain or loss in the Statement of Profit and Loss at initial recognition if the fair value is determined through a quoted market price in an active market for an identical asset (i.e. level 1 input) or through a valuation technique that uses data from observable markets (i.e. level 2 input).

In case the fair value is not determined using a level 1 or level 2 input as mentioned above, the difference between the fair value and transaction price is deferred appropriately and recognized as a gain or loss in the Statement of Profit and Loss only to the extent that such gain or loss arises due to a change in factor that market participants take into account when pricing the financial asset.

However, trade receivables that do not contain a significant financing component are measured at transaction price.

Subsequent measurement:

For subsequent measurement, the Company classifies a financial asset in accordance with the below criteria:

- The Company's business model for managing the financial assets and
- The contractual cash flow characteristics of the financial asset

Based on the above criteria, the Company classifies its financial assets subsequently in following categories:

- at amortized cost (AC),
- fair value through other comprehensive income (FVTOCI)
- fair value through profit and loss (FVPTL).

Financial assets carried at amortised cost (AC)

A financial asset is measured at amortised cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium and fees or costs that are an integral part of the EIR. The EIR amortization is included in finance income in the Statement of Profit and Loss. The losses arising from impairment are recognised in the Statement of Profit and Loss.

(ii) Financial Liabilities

Initial recognition and measurement:

The Company recognizes a financial liability in its Balance Sheet when it becomes party to the contractual provisions of the instrument. All financial liabilities are recognized initially at fair value minus, in the case of financial liabilities not recorded at fair value through profit or loss (FVTPL), transaction costs that are attributable to the acquisition of the financial liability.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

Where the fair value of a financial liability at initial recognition is different from its transaction price, the difference between the fair value and the transaction price is recognized as a gain or loss in the Statement of Profit and Loss at initial recognition if the fair value is determined through a quoted market price in an active market for an identical asset (i.e. level 1 input) or through a valuation technique that uses data from observable markets (i.e. level 2 input).

In case the fair value is not determined using a level 1 or level 2 input as mentioned above, the difference between the fair value and transaction price is deferred appropriately and recognized as a gain or loss in the Statement of Profit and Loss only to the extent that such gain or loss arises due to a change in factor that market participants take into account when pricing the financial liability.

Subsequent measurement

All financial liabilities of the Company are subsequently measured at amortized cost using the effective interest method, except for trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments. Under the effective interest method, the future cash payments are exactly discounted to the initial recognition value using the effective interest rate. The cumulative amortization using the effective interest method of the difference between the initial recognition amount and the maturity amount is added to the initial recognition value (net of principal repayments, if any) of the financial liability over the relevant period of the financial liability to arrive at the amortized cost at each reporting date. The corresponding effect of the amortization under effective interest method is recognized as interest expense over the relevant period of the financial liability. The same is included under finance cost in the Statement of Profit and Loss.

Trade and Other Payables

A payable is classified as 'trade payable' if it is in respect of the amount due on account of goods purchased or services received in the normal course of business. These amounts represent liabilities for goods and services provided to the Company which are unpaid. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method

Loans and Borrowings

After initial recognition, interest-bearing borrowings are subsequently measured at amortised cost using the effective interest rate method. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method. Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down.

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting period.

(j) Fair Value

The Company measures financial instruments at fair value in accordance with the accounting policies mentioned above. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the Principal market for assets or Liabilities or
- In the absence of a Principal market, in the most advantageous market for the assets or liability

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy that categorizes into three levels, described as follows, the inputs to valuation techniques used to measure value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1 inputs) and the lowest priority to unobservable inputs (Level 3 inputs).

Level 1 — quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3 — inputs that are unobservable for the asset or liability

(k) Employee Benefits

Short-term obligations

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognised in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled.

Long-term employee Benefits

Compensated absences which are not expected to occur within 12 months after the end of the period in which the employee renders the related services are recognized as a liability at the present value of the defined benefit obligation at the balance sheet date.

Post-Employment Benefits

Defined Contribution Plans:

A defined contribution plan is a post-employment benefit plan under which the Company pays specified contributions to a separate entity. The Company makes specified monthly contributions towards Provident Fund and Pension Scheme. The Company's contribution is recognised as an expense in the Statement of Profit and Loss during the period in which the employee renders the related service.

Defined Benefit Plan:

The Company's Liabilities on account of Gratuity and Earned Leave on retirement of employees are determined at the end of each financial year on the basis of actuarial valuation certificates obtained from Registered Actuary in accordance with the measurement procedure as per Indian Accounting Standard (INDAS)-19, 'Employee Benefits'. Liability against Gratuity are funded on year-to-year basis by contribution to respective fund. The costs of providing benefits under these plans are also determined on the basis of actuarial valuation at each year end. Actuarial gains and losses for defined benefit plans are recognized through OCI in the period in which they occur. Re-measurements are not reclassified to profit or loss in subsequent periods.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

(l) Borrowing Cost

Borrowing cost includes interest, amortization of ancillary costs incurred in connection with the arrangement of borrowings and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs, if any, directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized. All other borrowing costs are expensed in the period in which they occur.

(m) Lease

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

As a lessee

(A) Lease Liability

At the commencement date, the Company measures the lease liability at the present value of the lease payments that are not paid at that date. The lease payments shall be discounted using incremental borrowing rate.

(B) Right-of-use assets

Initially recognised at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives.

Subsequent measurement

(A) Lease Liability

Company measures the lease liability by (a) increasing the carrying amount to reflect interest on the lease liability; (b) reducing the carrying amount to reflect the lease payments made; and (c) remeasuring the carrying amount to reflect any reassessment or lease modifications.

(B) Right-of-use assets

Subsequently measured at cost less accumulated depreciation and impairment losses. Right-of-use assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset.

Short term lease:

Short term lease is that, at the commencement date, has a lease term of 12 months or less and lease of low value asset. A lease that contains a purchase option is not a short-term lease. If the company elected to apply short term lease, the lessee shall recognise the lease payments associated with those leases as an expense on either a straight-line basis over the lease term or another systematic basis. The lessee shall apply another systematic basis if that basis is more representative of the pattern of the lessee's benefit.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

As a lessor

Leases for which the company is a lessor is classified as a finance or operating lease. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

Lease income is recognised in the statement of profit and loss on straight line basis over the lease term.

(n) Earnings Per share

Basic earnings per share are calculated by dividing the profit or loss for the period attributable to equity shareholders (after deducting preference dividends, if any, and attributable taxes) by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effect of all dilutive potential equity shares.

(o) Income Taxes

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date.

Current income tax relating to items recognised directly in equity is recognised in equity and not in the statement of profit and loss. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

(p) Deferred tax

Deferred tax is provided using the balance sheet approach on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purpose at reporting date. Deferred income tax assets and liabilities are measured using tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that includes the enactment or the substantive enactment date. A deferred income tax asset is recognized to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences and tax losses can be utilized. The Company offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.

(q) Government Grant

Subsidies are measured at amount receivable from the Govt which are non-refundable and are recognized as income when there is reasonable assurance that the company will comply with all necessary condition attached to them. Income from subsidy is recognised on systematic basis over the period in which the related cost that are intended to be compensated by such subsidies are recognised.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN: U24301KA2010PTC055162

Notes to financial statements for the year ended 31 March, 2026

(r) Provisions

The Company recognizes provisions when a present obligation (legal or constructive) as a result of a past event exists and it is probable that an outflow of resources embodying economic benefits will be required to settle such obligation and the amount of such obligation can be reliably estimated.

If the effect of time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not require an outflow of resources embodying economic benefits or the amount of such obligation cannot be measured reliably. When there is a possible obligation or a present obligation in respect of which likelihood of outflow of resources embodying economic benefits is remote, no provision or disclosure is made.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

2 Property, Plant and Equipments

(Amount in Rs. Lakhs unless otherwise stated)

Assets	Gross Block			Depreciation/Amortisation			Net Block	
	As at 1st Apr 2025	Additions during the period	Deletions during the year	As at 31 March 2026	As at 1st Apr 2025	For the period	As at 31 March 2026	As at 31st Mar 2025
(A) ROU Assets								
Land - Right of Use Assets	568.89	1.58	-	570.47	12.42	6.32	18.74	551.73
(B) Tangible Assets								
Building	589.52	38.75	-	628.27	58.20	31.42	89.62	538.65
Plant & Machinery	977.21	162.92	13.81	1,126.32	114.21	68.83	170.58	955.74
Furniture & Fixture	4.20	-	-	4.20	2.67	0.20	2.87	1.33
Office Equipment	6.77	1.53	-	8.30	2.41	0.93	3.34	4.96
Computer	9.66	1.62	-	11.28	7.78	1.89	9.67	1.61
Vehicles	92.83	-	-	92.83	26.79	13.40	40.19	52.64
Electrical installations and equipment	40.87	1.87	-	42.74	7.19	3.82	11.01	31.73
Lab Equipments	10.55	1.58	-	12.13	4.38	1.03	5.41	6.72
Total Tangible Assets	2,300.50	209.85	13.81	2,496.54	236.05	127.84	351.43	2,145.11
								2,064.45

Assets	Gross Block			Depreciation/Amortisation			Net Block	
	As at 1st Apr 2024	Additions during the period	Deletions during the year	As at 31st Mar 2025	As at 1st Apr 2024	For the period	As at 31st Mar 2025	As at 31st Mar 2024
(A) ROU Assets								
Land - Right of Use Assets	495.30	73.59	-	568.89	3.72	8.70	12.42	556.47
(B) Tangible Assets								
Building	521.97	67.55	-	589.52	28.55	29.65	58.20	493.42
Plant & Machinery	836.88	198.99	58.66	977.21	57.19	63.53	114.21	863.00
Furniture & Fixture	4.00	0.20	-	4.20	1.81	0.86	2.67	1.53
Office Equipment	3.10	3.67	-	6.77	1.14	1.27	2.41	4.36
Computer	9.29	0.37	-	9.66	4.17	3.61	7.78	1.88
Vehicles	92.83	-	-	92.83	13.40	13.40	26.79	66.04
Electrical installations and equipment	38.62	2.25	-	40.87	3.49	3.70	7.19	33.68
Lab Equipments	10.55	-	-	10.55	2.50	1.88	4.38	6.17
Total Tangible Assets	2,012.54	346.62	58.66	2,300.50	115.97	126.60	236.05	1,896.57

2A Lease liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Lease Liabilities		
- Current	0.00	-
- Non-Current	2.34	-
Total Lease Liabilities	2.34	-



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

Capital Work-In-Progress

Capital Work-In-Progress ageing schedule

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 Years	2-3 years	More than 3 years	
Projects in progress					
31 March, 2026	1.87	-	-	-	1.87
31 March, 2025	-	-	-	-	-
Projects temporarily suspended					
31 March, 2026	-	-	-	-	-
31 March, 2025	-	-	-	-	-



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

3 Non-Current Other Financial Assets

	As at 31 March 2026	As at 31 March 2025
<i>Unsecured considered good</i>		
Security Deposits	32.73	32.73
Total	32.73	32.73

4 Non-Current Other Assets

	As at 31 March 2026	As at 31 March 2025
MAT credit entitlement	340.53	332.82
Total	340.53	332.82

5 Inventories

	As at 31 March 2026	As at 31 March 2025
Raw Materials	1,615.51	1,041.77
Work in progress	240.39	152.30
Finished Goods	577.11	665.67
Stock-in-trade	-	92.82
Total	2,433.01	1,952.56

6 Current Investments

	As at 31 March 2026	As at 31 March 2025
Measured at fair value through P&L(FVTPL)		
Investments in Units of Mutual Fund (Quoted)	11,116.32	8,069.93
Total	11,116.32	8,069.93
Aggregate book value of Quoted Investment	11,116.32	8,069.93



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

7 Trade Receivables

	As at 31 March 2026	As at 31 March 2025
<i>Secured</i>		
Considered good	136.61	-
<i>Unsecured</i>		
Considered good		
Considered doubtful	2,948.24	1,663.02
Less: allowance for doubtful trade receivables	(9.04)	-
Total	3,075.81	1,663.02

Trade Receivables Ageing Schedule as at 31 March, 2026

	Outstanding for following periods from due date of payment					Total
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	
(i) Undisputed Trade receivables – considered good	1,563.23	1,484.88	-	0.04	7.70	3,084.85
(ii) Undisputed Trade receivables – Considered Doubtful	-	-	-	-	-	-
(iii) Disputed Trade receivables – considered good	-	-	-	-	-	-
(iv) Undisputed Trade receivables – Considered Doubtful	-	-	-	-	-	-
Less: Allowance for doubtful trade receivables	-	-	-	0.04	7.70	3,084.85
Total Trade Receivables	1,563.23	1,484.88	-	0.04	6.93	3,075.81

Trade Receivables Ageing Schedule as at 31 March, 2025

	Outstanding for following periods from due date of payment					Total
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	
(i) Undisputed Trade receivables – considered good	1,105.09	499.25	4.30	11.69	18.95	1,663.02
(ii) Undisputed Trade receivables – Considered Doubtful	-	-	-	-	-	-
(iii) Disputed Trade receivables – considered good	-	-	-	-	-	-
(iv) Undisputed Trade receivables – Considered Doubtful	-	-	-	-	-	-
Less: Allowance for doubtful trade receivables	-	-	-	-	-	-
Total Trade Receivables	1,105.09	499.25	4.30	11.69	18.95	1,663.02



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

8 Cash and Cash Equivalents

	As at 31 March 2026	As at 31 March 2025
Balances with Banks :-		
- Current accounts	87.30	38.57
- Exchange earners foreign currency account	47.00	552.26
Cash in hand	1.26	1.07
Fixed Deposit (maturity less than 12 months)*	70.00	-
Total	205.56	591.90

lien against forward contracts*9 Other Current Financial Assets**

	As at 31 March 2026	As at 31 March 2025
Unsecured considered good		
Security Deposits	0.12	0.12
Interest Receivable	0.05	-
Total	0.17	0.12

10 Current Tax Assets

	As at 31 March 2026	As at 31 March 2025
Income tax refund relating to previous years	115.37	111.78
Total	115.37	111.78

11 Other Current Assets

	As at 31 March 2026	As at 31 March 2025
Prepaid Expenses	7.46	12.36
Capital Advances	0.00	-
Advance to Suppliers	3.65	-
Balance with Govt. Authorities	170.42	162.78
Total	181.53	175.14



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

12 Equity Share Capital**(a) Authorised**

Particulars	No. of Shares		Amount	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Equity Shares of Rs. 10 each				
At the beginning of the period	9,000,000	9,000,000	900.00	900.00
Add: Additions during the period	-	-	-	-
Less: Reduction during the period	-	-	-	-
At the end of the period	9,000,000	9,000,000	900.00	900.00

(b) Issued, subscribed and paid up

Particulars	No. of Shares		Amount	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Equity Shares of Rs. 10 each fully paid up				
At the beginning of the period	6,000,000	8,000,000	600.00	800.00
Add: Additions during the period	-	-	-	-
Less: Reduction during the period	-	2,000,000	-	200.00
At the end of the period	6,000,000	6,000,000	600.00	600.00

(c) Rights, preferences and restrictions attached to equity

The Company has only one class of equity shares having a par value of INR 10/- per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividend in Indian Rupees. The dividend proposed by the Board of Directors is subject to shareholders approval in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the equity share holders will be entitled to receive the remaining assets of the Company, after distribution of all preferential amounts, if any, in proportion to the number of equity shares held by the shareholders.

Company bought back and extinguished 20,00,000 equity shares in FY 2024-25 at a buyback price of Rs. 125 per equity share. As a result, the paid-up equity share capital of the Company stands reduced to that extent. The Company has drawn Rs. 2,882.44 lakhs from the retained earnings which were utilized for buy back of Rs. 2,500 Lakhs and Rs. 382.44 Lakhs for other transaction costs. In accordance with Section 69 of the Companies Act, 2013, the Company has created capital redemption reserve of Rs. 200 Lakhs equal to the face value of equity shares bought back as appropriation from retained earnings.

Details of shares in the company held by each shareholder holding more than 5% of shares is as under:

Name of the Shareholder	No. of Shares		Percentage		Change during the year
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025	
JK Paper Limited	3,900,000	3,728,400	65.00%	62.14%	2.86%
Cheluvarayaswamy Gopalswamy	522,179	576,800	8.70%	9.61%	-0.91%
Lakshmikanth Yadav	458,385	441,001	7.64%	7.35%	0.29%
Rajeevalochan Dinamani	631,421	576,800	10.52%	9.61%	0.91%

Promoters Shareholding

Name of Promoter	No. of Shares		Percentage		Change during the year
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025	
JK Paper Limited	3,900,000	3,728,400.00	65.00%	62.14%	2.86%
Cheluvarayaswamy Gopalswamy	522,179	576,800	8.70%	9.61%	-0.91%
Lakshmikanth Yadav	458,385	441,001	7.64%	7.35%	0.29%
Rajeevalochan Dinamani	631,421	576,800	10.52%	9.61%	0.91%



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

13 Non-Current Provisions

	As at 31 March 2026	As at 31 March 2025
Provisions for Employee Benefits		
- Gratuity	110.75	70.17
- Leave Encashment	20.85	18.28
Total	131.60	88.45

14 Deferred Tax Liability (Net)

	As at 31 March 2026	As at 31 March 2025
Deferred Tax Liability		
Fair value of mutual fund	429.93	368.92
Property, Plant and Equipments	67.49	49.70
ROU Asset	0.46	-
43B(h) - MSME	0.24	-
Timing differences - 40(a)(ia)	-	0.31
Total	498.12	418.93
Deferred Tax Assets		
Gratuity Benefits	38.89	22.80
Privilege Leave Benefits	6.52	6.10
Lease Liabilities	0.68	-
MTM on forward contracts	3.37	-
43B(h) - MSME	-	0.24
Total	49.46	29.14
Net Deferred Tax Liability / (Asset)	448.66	389.79

15 Current Borrowings

	As at 31 March 2026	As at 31 March 2025
Secured		
Working Capital Borrowing from Bank*	649.53	191.29
Current Maturities of Long Term Debts	-	-
Total	649.53	191.29

*Working Capital Borrowings are secured by hypothecation of Raw Materials, Finished Goods, Stock-in-Process, Stores & Spares and Book Debts. The same are further secured by a first charge on the movable and immovable assets of the Company.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

16 Trade Payables

(Amount in Rs. Lakhs unless otherwise stated)

	As at 31 March 2026	As at 31 March 2025
a) Total outstanding dues of micro enterprises and small enterprises	82.02	71.44
b) Total outstanding dues of Creditors other than micro enterprises and small enterprises	1,281.13	616.25
Total	1,363.15	687.69

Trade Payables Ageing Schedule as at 31 March, 2026

	Outstanding for following periods from due date of				Total
	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years
MSME	82.02	-	-	-	82.02
Others	1,191.30	85.34	2.30	-	1,281.13
Disputed dues - MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Total	1,273.32	85.34	2.30	-	1,363.15

Trade Payables Ageing Schedule as at 31 March, 2025

	Outstanding for following periods from due date of				Total
	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years
MSME	71.44	-	-	-	71.44
Others	590.15	4.30	19.61	2.19	616.25
Disputed dues - MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Total	661.59	4.30	19.61	2.19	687.69



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

17 Short Term Provisions

	As at 31 March 2026	As at 31 March 2025
Provisions for Employee Benefits		
- Gratuity	22.80	16.25
- Leave Encashment	1.53	2.68
Total	24.33	18.93

18 Other Current Liabilities

	As at 31 March 2026	As at 31 March 2025
Advance from Customers	66.12	0.20
Capital Creditors	11.46	-
Statutory Dues	123.07	19.35
Derivative Liability	11.56	-
Other Payables including employee payables	163.02	8.28
Total	375.24	27.83

19 Current Tax Liabilities (Net)

	As at 31 March 2026	As at 31 March 2025
Provision for Income Tax (Net of TDS,TCS and Advance Tax)	-	14.28
Total	-	14.28

20 Income Tax Asset - Current

	As at 31 March 2026	As at 31 March 2025
Provision for Income Tax (Net of TDS,TCS and Advance Tax)	93.14	-
Total	93.14	-



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

21 Revenue from Operations

	For the period ended 31 March 2026	For the year ended 31 March 2025
Sales of products	11,973.87	12,666.95
Other Operating Revenue		
Export Incentives/Benefits	40.42	12.62
Total	12,014.29	12,679.57

22 Other Income

	For the period ended 31 March 2026	For the year ended 31 March 2025
Interest		
- from Income tax	3.59	-
- from others	1.30	0.01
Net gain on the account of foreign exchange fluctuations	82.46	24.13
Gain on sale/fair value of mutual funds*	214.03	660.61
Profit on sale of fixed assets	1.42	-
Miscellaneous Income	0.03	0.02
Total	302.83	684.77

* Includes Fair Valuation Gain of Rs. 201.39 Lakhs (31 March, 2025 Rs. 91.83 Lakh).

23 Cost of material consumed

	For the period ended 31 March 2026	For the year ended 31 March 2025
Raw material at the beginning of the period	1,041.77	730.48
Add: Purchases during the period	6,145.14	6,479.03
Less: Raw material at the end of the period	1,615.51	1,041.77
Consumption during the period	5,571.40	6,167.74

24 Change in Inventories

	For the period ended 31 March 2026	For the year ended 31 March 2025
Opening Stock		
Finished Goods	665.67	390.24
Work in Progress	152.30	19.56
Stock in trade	92.82	129.67
Closing Stock		
Finished Goods	577.11	665.67
Work in Progress	240.39	152.30
Stock in trade	-	92.82
(Increase)/Decrease in stocks	93.29	(371.32)



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

26 Finance Costs

	For the period ended 31 March 2026	For the year ended 31 March 2025
Interest on		
- Borrowings from bank	20.01	20.17
- Lease Liabilities	0.10	-
Total	20.11	20.17

27 Depreciation and amortisation expenses

	For the period ended 31 March 2026	For the year ended 31 March 2025
Depreciation on Property, Plant and Equipment	121.52	117.90
Amortisation of ROU Asset	6.32	8.70
Total	127.84	126.60

28 Other Expenses

	For the period ended 31 March 2026	For the year ended 31 March 2025
Packing and forwarding (net)	337.96	343.62
Jobwork charges	121.39	118.50
Calibration and stack monitoring charges	49.59	103.58
Power and Fuel	282.18	272.39
Legal and professional expenses	241.99	196.95
Travelling and conveyance	77.86	58.61
Repairs to Machinery	52.40	58.78
Repairs to Buildings	9.29	5.20
Repairs to Others	5.67	5.54
Palletisation, fumigation and radiation expenses	49.00	34.24
Bank Charges	19.89	15.87
Rent	16.25	18.92
Provision for bad and doubtful debts	9.04	-
MTM loss on derivative	11.56	-
Rates and Taxes	10.61	5.10
Security expenses	9.17	8.81
Insurance	6.39	3.44
Audit fees (refer note 28(i) below)	6.00	4.50
Corporate Social Responsibility expenses (refer note 28(ii) below)	61.00	43.75
Water charges	7.36	6.75
Sample and testing expenses	8.09	7.22
Director Sitting fees	3.43	-
Communication expenses	2.49	2.29
Printing & stationery	3.53	2.19
Loss on sale of fixed assets	-	21.62
Miscellaneous expenses	21.27	18.05
Total	1,423.41	1,355.92

28(i) Details of payment made to statutory auditors

	For the period ended 31 March 2026	For the year ended 31 March 2025
As Statutory Audit Fees	3.50	2.50
As Tax Audit Fees	1.00	2.00
Total	4.50	4.50



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

28(ii) Details of payment made for Corporate Social Responsibility

	For the period ended 31 March 2026	For the year ended 31 March 2025
Amount required to be spent by the company during the year	61.00	43.73
Amount of Expenditure contributed to Trust	-	43.75
Actual amount spent	61.00	-
Shortfall at the end of the year	-	-
Total of previous year shortfall	-	-
Reason for shortfall	-	-
Nature of CSR activities	Education, Health & Environment / Nature	
Details of related party transaction	Nil	Nil

29 Earning Per Share (EPS)

	For the period ended 31 March 2026	For the year ended 31 March 2025
Basic and Diluted Earnings Per Share		
Profit/(Loss) after tax as per profit and loss account (Rs. Lakh)	3,177	3,818
Weighted Average Number of Equity Shares	6,000,000	7,003,704
Basic and Diluted Earning Per Share (Rs.)	52.96	54.51

30 Contingent Liabilities & Commitments (to the extent not provided for)

Particulars	As at 31 March 2026	As at 31 March 2025
a) Claim against the company not acknowledged as debts	-	-
b) Commitments:	-	-
Contracts remaining to be executed on capital account (net of advances)		

31 The Micro, Small And Medium Enterprises Development (MSMED) Act, 2006

Based on the information available, there are certain vendors who have confirmed that they are covered under the Micro, Small and Medium Enterprises Development Act, 2006. Disclosures relating to dues of Micro and Small enterprises under section 22 of 'The Micro, Small and Medium Enterprises Development Act, 2006, are given below:

	As at 31 March 2026	As at 31 March 2025
(a) Principal amount and Interest due thereon remaining unpaid to any supplier as on	-	-
(b) 'Interest paid by the Company in terms of Section 16 of the MSMED Act along with the amounts of the payment made to the supplier beyond the appointed day during the accounting year.	-	-
(c) the amount of interest due and payable for the year of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Act	-	-
(d) the amount of interest accrued and remaining unpaid	-	-
(e) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of this Act	-	-



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

25 Employee benefit expenses

	For the period ended 31 March 2026	For the year ended 31 March 2025
Salaries and Wages	948.59	856.46
Contribution to Provident and Other Funds	88.64	45.26
Staff Welfare Expenses	34.53	33.81
Total	1,071.76	935.53

Refer Note 25.1 for actuarial assumptions

25.1 Disclosure as required by Indian Accounting Standard (Ind AS) 19 Employee Benefits.
Defined Benefit Plans :
Changes in the present value of the obligations

	Gratuity (funded)		Leave Benefits (unfunded)	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Present value of defined benefit obligation at the beginning of the year	150.82	124.35	20.96	17.38
Interest cost	8.17	7.28	1.31	1.20
Past Service Cost	15.63	-	-	-
Current service cost	30.88	17.55	3.21	1.94
Benefits Paid	(8.46)	(5.19)	(2.13)	(0.21)
Actuarial (gain)/loss on obligations	10.66	6.83	(0.97)	0.65
Present value of defined benefit obligation at the end of the year	207.70	150.82	22.38	20.96

Change in fair value of plan asset

	Gratuity (funded)		Leave Benefits (unfunded)	
	For the period ended 31 March 2026	For the year ended 31 March 2025	For the period ended 31 March 2026	For the year ended 31 March 2025
Present value of Plan assets at the beginning of the year	64.40	58.42	-	-
Expected return on Plan Assets	3.00	3.09	-	-
Return on plan assets excluding interest income	1.43	1.33	-	-
Contributions	11.10	6.75	-	-
Benefits paid	(5.78)	(5.19)	-	-
Charges Deducted	-	-	-	-
Fair value of plan assets at the end of the year	74.15	64.40	-	-

Reconciliation of Present value of Defined Benefit Obligation and Fair Value of Plan Assets

	Gratuity (funded)		Leave Benefits (unfunded)	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Present value of defined benefit obligation at the end of the year	207.70	150.82	22.38	20.96
Fair value of plan assets at the end of the year	74.15	64.40	-	-
Funded Status (Surplus/(Deficit))	(133.55)	(86.42)	(22.38)	(20.96)
Net Asset/(Liability)	(133.55)	(86.42)	(22.38)	(20.96)

Amount recognized in Balance Sheet

	Gratuity (funded)		Leave Benefits (unfunded)	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Present value of obligation as at the end of the year	207.70	150.82	22.38	20.96
Fair value of Plan Assets as at the end of the year	74.15	64.40	-	-
Unfunded Net Assets/(Liability) recognised in Balance Sheet	133.55	86.42	22.38	20.96

Expenses Recognized in Profit & Loss

	Gratuity (funded)		Leave Benefits (unfunded)	
	For the period ended 31 March 2026	For the year ended 31 March 2025	For the period ended 31 March 2026	For the year ended 31 March 2025
Current Service Cost	30.88	17.55	3.21	1.94
Past Service Cost	15.63	-	-	-
Interest Cost	5.17	7.28	1.31	1.20
Remeasurement on the obligation and plan assets	-	(3.09)	(0.97)	-
Total Expenses recognised in Profit & Loss Account	51.68	21.74	3.55	3.14

Recognized in Other Comprehensive Income (OCI)

Particulars	Gratuity (funded)		Leave Benefits (unfunded)	
	For the period ended 31 March 2026	For the year ended 31 March 2025	For the period ended 31 March 2026	For the year ended 31 March 2025
Net Actuarial (Gain)/Loss	10.66	6.83	-	0.65
Expected return on Plan Assets excluding interest income	(1.43)	(1.33)	-	-
Total Actuarial (gain)/loss at the end of the year	9.23	5.50	-	0.65

Actuarial Assumptions

Particulars	Gratuity (funded)		Leave Benefits (unfunded)	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
Discount rate (per annum)	7.25%	6.60%	7.25%	6.70%
Rate of increase in Compensation Levels (Per Annum)	10.00%	10.00%	10.00%	10.00%
Withdrawal/Attrition rate	8.00%	8.00%	8.00%	8.00%
Mortality Rate During Employment	Indian Assured Lives Mortality 2012-14	Indian Assured Lives Mortality 2012-14	Indian Assured Lives Mortality 2012-14	Indian Assured Lives Mortality 2012-14



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

32 FINANCIAL INSTRUMENTS**Financial Assets**

Sl. No	Particulars	As at 31 March 2026		As at 31 March 2025	
		Carrying Amount	Fair Value	Carrying Amount	Fair Value
1	Financial assets designated at fair value through profit and loss				
	Investment in mutual funds	11,116.32	11,116.32	8,069.93	8,069.93
2	Financial assets designated at fair value through other comprehensive income	-	-	-	-
3	Financial assets designated at amortised cost				
	Other Bank Balances	-	-	-	-
	Cash & Cash Equivalents	205.56	205.56	591.90	591.90
	Trade receivables	3,075.81	3,075.81	1,663.02	1,663.02
	Other financial assets	32.89	32.89	32.85	32.85
Total		14,430.58	14,430.58	10,357.70	10,357.70

Financial Liabilities

Sl. No	Particulars	As at 31 March 2026		As at 31 March 2025	
		Carrying Amount	Fair Value	Carrying Amount	Fair Value
1	Financial liability designated at fair value through profit and loss	-	-	-	-
2	Financial liability designated at amortised cost				
	Borrowings	649.53	649.53	191.29	191.29
	Trade payables	1,363.15	1,363.15	687.69	687.69
	Other financial liability	-	-	-	-
Total		2,012.68	2,012.68	878.98	878.98

The fair value of financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

Fair value hierarchy

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

33 Financial risk management objectives and policies**33.1 Financial Risk Factors**

The Company's operational activities expose to various financial risks i.e. market risk, credit risk and risk of liquidity. The Company realizes that risks are inherent and integral aspect of any business. The primary focus is to foresee the unpredictability of financial markets and seek to minimize potential adverse effects on its financial performance. The primary market risk to the Company is foreign exchange risk & interest rate risk. The Company calculates and compares the alternative sources of funding by including cost of currency cover also. Whenever, the currency cover costs are such as to neutralize the advantage in foreign currency, loans are hedged so as to not to lose advantage. The Company uses derivative financial instruments to reduce foreign exchange risk exposures.

i. Credit Risk

The Company evaluates the customer credentials carefully from trade sources before appointment of any distributor and only financially sound parties are appointed as distributors. The Company secures adequate deposits from its Customers and hence risk of bad debt is limited. The credit outstanding is sought to be limited to the sum of advances/deposits and credit limit determined by the company. The company has stopped supply mechanism in place in case outstanding goes beyond agreed limits.

ii. Market Risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to fluctuation in market prices. These comprise three types of risk i.e. currency rate, interest rate and other price related risks. Financial instruments affected by market risk include loans and borrowings. Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Regular interaction with bankers, intermediaries and the market participants help us to mitigate such risk.

a) Foreign Currency Risk and sensitivity

The primary market risk to the Company is foreign exchange risk. The Company uses derivative financial instruments to reduce foreign exchange risk exposures and follows its risk management policies to mitigate the same. After taking cognisance of the natural hedge, the company takes appropriate hedges to mitigate its risk resulting from fluctuations in foreign currency exchange rate(s).

The following table analyzes foreign currency risk from financial instruments as of March 31, 2026:

Particulars	USD	Euro	Total
Financial Assets			
Cash and cash equivalents	47.00	-	47.00
Trade receivables	3,139.55	-	3,139.55
Other financials assets (including loans)	-	-	-
Total financial assets	3,186.55	-	3,186.55
Financial liabilities			
Trade payables	(588.52)	-	(588.52)
Other financials liabilities	-	-	-
Borrowings	(649.53)	-	(649.53)
Interest Accrued but not due	-	-	-
Total financial liability	(1,238.05)	-	(1,238.05)
Net assets / (liabilities)	1,948.50	-	1,948.50



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

The following table analyzes foreign currency risk from financial instruments as of March 31, 2025:

Particulars	USD	Euro	Total
Financial Assets			
Cash and cash equivalents	552.26	-	552.26
Trade receivables	1,065.14	35.40	1,100.54
Total financial assets	1,617.40	35.40	1,652.80
Financial liabilities			
Trade payables	(453.89)	-	(453.89)
Other financial liabilities	(13.67)	-	(13.67)
Borrowings	-	-	-
Interest Accrued but not due	-	-	-
Total financial liabilities	(467.56)	-	(467.56)
Net assets / (liabilities)	1,149.84	35.40	1,185.24

The following significant exchange rates have been applied during the year.

	Year-end exchange rates	
	31 March, 2026	31 March, 2025
USD	93.86	85.43
EUR	108.09	92.45

Foreign Currency Sensitivity

Sensitivity analysis is computed based on the changes in the income and expenses in foreign currency upon conversion into functional currency, due to exchange rate fluctuations between the previous reporting period and the current reporting period.

0.25% Increase and decrease in foreign exchanges rates will have the following impact on profit before tax

Particulars	2025-26		2024-25	
	Increase	Decrease	Increase	Decrease
USD Sensitivity	4.87	(4.87)	2.87	(2.87)
Euro Sensitivity	-	-	0.09	(0.09)
Increases/ (decrease) in profit or loss	4.87	(4.87)	2.96	(2.96)

Summary of exchange difference accounted in Statement of Profit and loss:

Particulars	For the period ended 31 March 2026	For the year ended 31 March 2025
Currency fluctuations		
Net foreign exchange (gain)/ losses shown as operating expenses	-	-
Net foreign exchange (gain)/ losses shown as Finance Cost	-	-
Net foreign exchange (gain)/ losses shown as Other Income	(82.46)	(24.13)
Derivatives		
Currency forwards (gain) / losses shown as operating expenses	11.56	-
Interest rate swaps (gain) / losses shown as finance cost	-	-
Net foreign exchange (gain)/ losses shown as Other Income	-	-
Total	(70.90)	(24.13)

b. Interest Rate Risk and Sensitivity

The Company's exposure to the risk of changes in market interest rates relates primarily to long term debt. Borrowings at variable rates exposes to cash flow risk. With all other variables held constant, the following table demonstrates composition of fixed and floating rate borrowing of the company and impact of floating rate borrowings on company's profitability.

Interest Rate Risk Exposure

Particulars	As at 31 March 2026		As at 31 March 2025	
	Amount	% of Total	Amount	% of Total
Fixed Rate Borrowings	-	-	-	-
Variable Rate Borrowings	649.53	100.00%	191.29	100.00%
Total Borrowings	649.53	100.00%	191.29	100.00%

Sensitivity on variable rate borrowings

Particulars	Impact on Profit & Loss Account		Impact on Equity	
	31 March, 2026	31 March, 2025	31 March, 2026	31 March, 2025
Interest Rate Increase by 0.25%	(1.62)	(1.98)	(1.62)	(1.98)
Interest Rate decrease by 0.25%	1.62	1.98	1.62	1.98

c. Commodity price risk and sensitivity

The Company is exposed to the movement in price of key raw materials in domestic and international markets. The Company has in place policies to manage exposure to fluctuations in the prices of the key raw materials used in operations. The Company manages fluctuations in raw material price through hedging in the form of advance procurement when the prices are perceived to be low and also enters into advance buying contracts as strategic sourcing initiative in order to keep raw material and prices under check cost of material hedged to the extent possible.



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

(Amount in Rs. Lakhs unless otherwise stated)

Credit Risk

Credit risk refers to the risk of default on its obligation by the counterparty resulting in a financial loss. The maximum exposure to the credit risk at the reporting date is primarily from trade receivables amounting to Rs.3,841.54 lakh and Rs.1,663.02 lakh as of March 31, 2026 and March 31, 2025, respectively. Trade receivables are typically unsecured and are derived from revenue earned from customers primarily located outside India. Credit risk has always been managed by the company through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business. On account of adoption of Ind AS 109, the company uses expected credit loss model to assess the impairment loss or gain. The Company uses a provision matrix to compute the expected credit loss allowance for trade receivables. The provision matrix takes into account as per the Company's historical experience for customers.

The following table gives details in respect of percentage of revenues generated from top customer and top five customers:

Particulars	(In %)	
	Year ended March 31,	
	2026	2025
Revenue from top customer	38.18%	49.65%
Revenue from top five customers*	63.79%	74.07%

* includes the top customer also

Credit risk exposure

The allowance for lifetime expected credit loss on customer balances for the year ended March 31, 2026 was Rs. Nil.

The fixed deposits with banks are marked as lien against the margin for the forward contracts

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The objective of liquidity risk management is to maintain sufficient liquidity and to ensure funds are available for use as per the requirement. The company has an established liquidity risk management framework for managing its short term, medium term and long term funding and liquidity management requirements. The company's exposure to liquidity risk arises primarily from mismatches of the maturities of financial assets and liabilities. The company manages the liquidity risk by maintaining adequate funds in cash and cash equivalents. The company also has adequate credit facilities agreed with the banks to ensure that there is sufficient cash to meet all its normal operating commitments in a timely and cost effective manner.

The table below provides details regarding the contractual maturities of significant financial liabilities as of 31 March, 2026:

Particulars	Carrying Amount	Less than 1 year	1-5 years	More Than 5 Year	Total
Borrowings - Current	649.53	649.53	-	-	649.53
Trade payables	1,363.15	1,358.66	4.49	-	1,363.15
Derivative Financial Instruments	11.56	11.56	-	-	11.56

The table below provides details regarding the contractual maturities of significant financial liabilities as of March 31, 2025:

Particulars	Carrying Amount	Less than 1 year	1-5 years	More Than 5 Year	Total
Borrowings - Current	191.29	191.29	-	-	191.29
Trade payables	687.69	665.89	21.80	-	687.69
Derivative Financial Instruments	-	-	-	-	-

33.2 Competition and Price risk

The Company faces competition from local and foreign competitors. Nevertheless, it believes that it has competitive advantage in terms of high quality products and by continuously upgrading its expertise and range of products to meet the needs of its customers.

33.3 Capital Risk Management

The Company's policy is to maintain an adequate capital base so as to maintain creditor and market confidence and to sustain future development. Capital includes issued capital, share premium and all other equity reserves attributable to equity holders. In order to strengthen the capital base, the company may use appropriate means to enhance or reduce capital, as the case may be

34 Foreign Currency Exposure not hedged

Sr. No.	Foreign Currency	As at 31 March 2026		As at 31 March 2025	
		Foreign Currency	Amount	Foreign Currency	Amount
1	US Dollar	-	-	13.46	1,149.84
2	Euro	-	-	0.38	35.40



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

35 Related Party

A Name of the party

Relationship

(a) Holding and Subsidiary companies

JK Paper Limited

Holding Company

(b) Key Managerial Person

Shri Lakshmikanth Yadav

Managing Director (ceases w.e.f 24 March, 2025)

Shri Rajeevlochan Dinamani

Executive Director (w.e.f. 25 March, 2025)

Shri C Gopalaswamy

Executive Director

Shri Harsh Pati Singhania

Director (ceases w.e.f 25 March, 2025)

Shri Chaitanya Hari Singhania

Non-Executive Director (w.e.f. 25 March, 2025)

Shri Amar Singh Mehta

Non-Executive Director (w.e.f. 25 March, 2025)

Shri Karuppan Chetty Veerappan

Non-Executive Director (w.e.f. 25 March, 2025)

Shri Sushil Kumar Wali

Non-Executive Director (w.e.f. 25 March, 2025, ceases w.e.f. 08 May, 2025)

Shri Anoop Seth

Independent Director (w.e.f. 08 May, 2025)

Independent Director (w.e.f. 08 May, 2025)

B Details of transaction with the related parties mentioned above:

Name of the Party	Nature of Transaction	Amount	
		For the period ended 31 March 2026	For the year ended 31 March 2025
Key Managerial Person	Short Term Employee Benefits	466.95	451.43
Key Managerial Person	Sitting Fees	3.43	-

C Details of closing balances with the related parties mentioned above:

Name of the Party	Nature of Transaction	Closing Balance	
		As at 31 March 2026	As at 31 March 2025
Key Managerial Person	Short Term Employee Benefits	200.00	-
Key Managerial Person	Sitting Fees	-	-

36 Income Tax

a) Amount recognised in Statement of Profit and Loss

Particulars	As at 31 March 2026	As at 31 March 2025
Current Income Tax		
Current year	716.71	791.90
MAT Credit Entitlement		
Current year recognized	-	0.14
Total	716.71	792.04
Deferred Tax	58.87	61.60
Income tax expense reported in the statement of profit and loss	775.59	853.64

b) Reconciliation of Effective Tax Rate

Particulars	As at 31 March 2026	As at 31 March 2025
Profit/(Loss) before tax	3,952.97	4,671.32
At applicable Statutory Income Tax Rate CY- 29.12 %	1,151.10	1,360.29
Tax Impact on:-		
Deduction under Section 10AA	(384.03)	(433.75)
Donation	8.88	(6.37)
Different tax rates on Capital Gain	-	(55.81)
Others	(0.36)	(10.71)
Reported Income Tax Expense	775.59	853.64
Effective Tax Rate	19.62%	18.27%



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

37 Ratio Analysis

Particulars	Unit	31 March, 2026	31 March, 2025	Variance	Variance %	Reason for variance
(a) Current Ratio	Times	7.09	13.60	-6.51	-47.85%	Refer remark (i) below
(b) Debt-Equity Ratio	Times	0.04	0.01	0.02	175.27%	Refer remark (i) below
(c) Debt Service Coverage Ratio	Times	NA	NA	NA	NA	
(d) Return on Equity Ratio	%	20.96%	28.90%	-7.94%	-7.94%	
(e) Inventory Turnover Ratio	Times	5.46	7.87	-2.41	-30.61%	Refer remark (ii) below
(f) Trade Receivable Turnover Ratio	Times	5.19	7.17	-1.98	-27.56%	Refer remark (iii) below
(g) Trade Payable Turnover Ratio	Times	11.99	9.98	2.01	20.14%	
(h) Net Capital Turnover Ratio	Times	0.81	1.09	-0.28	-25.29%	Refer remark (i) below
(i) Net Profit Ratio	%	26.45%	30.11%	-3.66%	-3.66%	
(j) Return on Capital Employed	%	27.00%	33.34%	-6.34%	-6.34%	
(k) Return on Investment-Mutual Funds	%	2.23%	7.74%	-5.51%	-5.51%	

*NA - Not Applicable

Note:

(i) The borrowings for the Company has increased by Rs. 458.24 lakhs

(ii) The inventory of the Company has increased during the current year

(iii) The Company's trade receivables has increased in the current year by Rs. 2,178.52 lakhs



QUADRAGEN VETHEALTH PRIVATE LIMITED

CIN : U24301KA2010PTC055162

Notes to the Standalone Financial Statements as at and for the period ended

38 Audit Trail

The Company has been maintaining its books of accounts in the accounting software "Tally" which has feature of recording audit trail of each and every transaction, creating an edit log of each change made in books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled effective 24 April, 2024.

39 Segment information

The Company has only one business segment i.e. Animal Nutrition Products including Feed Additives & Growth Promoters. The performance is reviewed by the Board of Directors (Chief operating decision makers).

During the year a single customer contributed to more than 10% of the total sale of products for Rs. 4,862.49 lakhs 31 March, 2026 (31 March, 2025 Rs. 6,295 lakhs).

40 Additional Regulatory Information

- i) The Company does not own any immovable property (other than immovable properties where the Company is the lessee and lease agreements are duly executed in favour of the Company).
- ii) The company does not have any investment property.
- iii) During the year the company has not revalued its property, plant and Equipment.
- iv) During the year the company has not revalued its intangible assets.
- v) During the year the company has not granted any Loan or advance in the nature of loans to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013), either severally or jointly with any other person that are:
 - a. repayable on demand ; or
 - b. without specifying any terms or period of repayment,
- vi) The company does not have intangible assets under development.
- vii) No proceeding has been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
- viii) The company has borrowings from banks or financial institution on the basis of security of current assets and quarterly returns or statement of current assets filed by the company with banks or financial institutions are in agreement with books of accounts.
- ix) The company is not declared wilful defaulter by any bank or financial institution or other lender.
- x) The company has not entered into any transaction with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956.
- xi) No charges or satisfaction yet to be registered with ROC beyond the statutory period.
- xii) The Company has complied with the number of layers prescribed under clause (87) of section 2 of the act read with companies (Restriction on number of layers) rule 2017.
- xiii) Utilisation of Borrowed funds and share premium:-
 - A) The company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall
 - (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries;
 - (B) The company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall
 - (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries
- xv) The company has not traded or invested in crypto currency or virtual currency during the year.

41 Amount presented as 0.00 are rounded off to the nearest lakhs and not to be considered as NIL

42 Previous year figures have been regrouped/ rearranged, wherever considered necessary to confirm to current year's classification.

As per our report of even date annexed
For N Adinarayana & Associates
Chartered Accountants

N Adinarayana

N Adinarayana

Proprietor

Membership No :- 202948

Firm Registration No:- 0070865

UDIN: 26202948EHJXTU5554

Place: Bangalore

Date: 8 May, 2026



For and on behalf of the Board of Directors

Lakshmikanth Yadav

Lakshmikanth Yadav

Executive Director

DIN. 03171140

Place: New Delhi

Date: 8 May, 2026

Rajeevalochan Dinamani

Rajeevalochan Dinamani

Executive Director

DIN. 03171174

Place: New Delhi

Date: 8 May, 2026